Found: 166
Select item for more details and to access through your institution.
The Change of Original‐ and Generic‐Targeted Antitumor Drugs under the National Centralized Drug Procurement Policy in Hohhot: An Interrupted Time‐Series Analysis.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2024, v. 2024, p. 1, doi. 10.1155/2024/6469912
- By:
- Publication type:
- Article
Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2024, v. 2024, p. 1, doi. 10.1155/2024/5437090
- By:
- Publication type:
- Article
Nuclear Receptors and Stress Response Pathways Associated with the Development of Oral Mucositis Induced by Antineoplastic Agents.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 8, p. 1086, doi. 10.3390/ph17081086
- By:
- Publication type:
- Article
Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer.
- Published in:
- Integrative Cancer Therapies, 2022, v. 21, p. 1, doi. 10.1177/15347354221144311
- By:
- Publication type:
- Article
Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial.
- Published in:
- Integrative Cancer Therapies, 2022, v. 21, p. 1, doi. 10.1177/15347354221086663
- By:
- Publication type:
- Article
P8‐169: Comparison of the efficacy of gefitinib and afatinib in pulmonary adenocarcinoma therapy with positive EGFR mutations in Javanese race.
- Published in:
- Respirology, 2021, v. 26, p. 354, doi. 10.1111/resp.14150_681
- Publication type:
- Article
P8‐150: Real world study of afatinib and erlotinib as firstline therapy of positive EGFR mutation Javanese lung adenocarcinoma.
- Published in:
- Respirology, 2021, v. 26, p. 347, doi. 10.1111/resp.14150_662
- Publication type:
- Article
P8‐120: Therapeutic efficacy of osimertinib following afatinib for the rare EGFR mutation exon19 delL747_P753insS: A case report.
- Published in:
- Respirology, 2021, v. 26, p. 335, doi. 10.1111/resp.14150_632
- Publication type:
- Article
P8‐93: Relationship between efficacy of afatinib and plasma EGFR mutation in osimertinib‐resistant patients with EGFR mutated lung cancer; NJLCG1801B study.
- Published in:
- Respirology, 2021, v. 26, p. 325, doi. 10.1111/resp.14150_605
- Publication type:
- Article
P8‐31: Prospective observational study of sequential afatinib and osimertinib in NSCLC patients with EGFR mutation: Gio‐Tag Japan.
- Published in:
- Respirology, 2021, v. 26, p. 299, doi. 10.1111/resp.14150_543
- Publication type:
- Article
P8‐15: Usefulness of liquid biopsy for patients with non‐small cell lung cancer harboring an EGFR mutation treated with afatinib.
- Published in:
- Respirology, 2021, v. 26, p. 292, doi. 10.1111/resp.14150_527
- Publication type:
- Article
P8‐9: Genomics on circulating tumor DNA predicts survival under afatinib treatment for EGFR‐ mutated non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 290, doi. 10.1111/resp.14150_521
- Publication type:
- Article
P8‐169: Comparison of the efficacy of gefitinib and afatinib in pulmonary adenocarcinoma therapy with positive EGFR mutations in Javanese race.
- Published in:
- Respirology, 2021, v. 26, p. 354, doi. 10.1111/resp.14150_681
- Publication type:
- Article
P8‐150: Real world study of afatinib and erlotinib as firstline therapy of positive EGFR mutation Javanese lung adenocarcinoma.
- Published in:
- Respirology, 2021, v. 26, p. 347, doi. 10.1111/resp.14150_662
- Publication type:
- Article
P8‐120: Therapeutic efficacy of osimertinib following afatinib for the rare EGFR mutation exon19 delL747_P753insS: A case report.
- Published in:
- Respirology, 2021, v. 26, p. 335, doi. 10.1111/resp.14150_632
- Publication type:
- Article
P8‐93: Relationship between efficacy of afatinib and plasma EGFR mutation in osimertinib‐resistant patients with EGFR mutated lung cancer; NJLCG1801B study.
- Published in:
- Respirology, 2021, v. 26, p. 325, doi. 10.1111/resp.14150_605
- Publication type:
- Article
P8‐31: Prospective observational study of sequential afatinib and osimertinib in NSCLC patients with EGFR mutation: Gio‐Tag Japan.
- Published in:
- Respirology, 2021, v. 26, p. 299, doi. 10.1111/resp.14150_543
- Publication type:
- Article
P8‐15: Usefulness of liquid biopsy for patients with non‐small cell lung cancer harboring an EGFR mutation treated with afatinib.
- Published in:
- Respirology, 2021, v. 26, p. 292, doi. 10.1111/resp.14150_527
- Publication type:
- Article
P8‐9: Genomics on circulating tumor DNA predicts survival under afatinib treatment for EGFR‐ mutated non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 290, doi. 10.1111/resp.14150_521
- Publication type:
- Article
EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 12, p. 3561, doi. 10.3390/cells10123561
- By:
- Publication type:
- Article
"From molecular to clinic": The pivotal role of CDC42 in pathophysiology of human papilloma virus related cancers and a correlated sensitivity of afatinib.
- Published in:
- Frontiers in Immunology, 2023, v. 14, p. 1, doi. 10.3389/fimmu.2023.1118458
- By:
- Publication type:
- Article
Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non--Small Cell Lung Cancer: Updated Analysis of the RESET Study.
- Published in:
- Cancer Research & Treatment, 2023, v. 55, n. 4, p. 1152, doi. 10.4143/crt.2023.493
- By:
- Publication type:
- Article
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
- Published in:
- Cancer Research & Treatment, 2023, v. 55, n. 2, p. 479, doi. 10.4143/crt.2022.1344
- By:
- Publication type:
- Article
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
- Published in:
- Cancer Research & Treatment, 2019, v. 51, n. 2, p. 502, doi. 10.4143/crt.2018.117
- By:
- Publication type:
- Article
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer.
- Published in:
- Cancer Research & Treatment, 2017, v. 49, n. 4, p. 1001, doi. 10.4143/crt.2016.546
- By:
- Publication type:
- Article
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-40349-z
- By:
- Publication type:
- Article
Complete response to afatinib in lung adenocarcinoma of epidermal growth factor receptor exon-19 deletion mutation and disease recurrence on drug discontinuation.
- Published in:
- Journal of Pharmacology & Pharmacotherapeutics, 2018, v. 9, n. 4, p. 191, doi. 10.4103/jpp.JPP_111_18
- Publication type:
- Article
Mechanisms of acquired resistance to afatinib clarified with liquid biopsy.
- Published in:
- PLoS ONE, 2018, v. 13, n. 12, p. 1, doi. 10.1371/journal.pone.0209384
- By:
- Publication type:
- Article
Relationship between Epidermal Growth Factor Receptor Mutations and Adverse Events in Non-Small Cell Lung Cancer Patients treated with Afatinib.
- Published in:
- Journal of Medical Investigation, 2021, v. 68, n. 1/2, p. 125, doi. 10.2152/jmi.68.125
- By:
- Publication type:
- Article
The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-11956-w
- By:
- Publication type:
- Article
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-11891-w
- By:
- Publication type:
- Article
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-11891-w
- By:
- Publication type:
- Article
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature.
- Published in:
- Oncology & Therapy, 2022, v. 10, n. 1, p. 291, doi. 10.1007/s40487-022-00183-7
- By:
- Publication type:
- Article
In-silico Interaction studies of curcumin and structurally related commercial drug afatinib and bicalutamide with probable anticancer targets.
- Published in:
- Chemistry & Biology Interface, 2021, v. 11, n. 5, p. 144
- By:
- Publication type:
- Article
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.709877
- By:
- Publication type:
- Article
A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.700345
- By:
- Publication type:
- Article
Research Progress and New Perspectives of Anticancer Effects of Emodin.
- Published in:
- American Journal of Chinese Medicine, 2023, v. 51, n. 7, p. 1751, doi. 10.1142/S0192415X23500787
- By:
- Publication type:
- Article
The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma.
- Published in:
- Cellular Oncology (2211-3428), 2022, v. 45, n. 4, p. 601, doi. 10.1007/s13402-022-00686-5
- By:
- Publication type:
- Article
Osimertinib 80 mg EOD? Does this work?
- Published in:
- Proceedings of Singapore Healthcare, 2022, v. 31, p. 1, doi. 10.1177/20101058221114743
- By:
- Publication type:
- Article
Recurrent Transient Asymptomatic Pulmonary Opacity with Long-Term Afatinib: A Case Report.
- Published in:
- Case Reports in Oncology, 2023, v. 16, n. 1, p. 173, doi. 10.1159/000529894
- By:
- Publication type:
- Article
Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report.
- Published in:
- Case Reports in Oncology, 2019, v. 12, n. 2, p. 564, doi. 10.1159/000501848
- By:
- Publication type:
- Article
Rapid Response to High-Dose, Pulsatile Erlotinib in Afatinib-Refractory Leptomeningeal Carcinomatosis from Adenocarcinoma of the Lung: A Case Report.
- Published in:
- Case Reports in Oncology, 2016, v. 9, n. 3, p. 537, doi. 10.1159/000449405
- By:
- Publication type:
- Article
Afatinib as First-Line Treatment in Elderly Patients with EGFR-Mutant Non-Small Cell Lung Cancer: Real-World Data Analysis.
- Published in:
- International Journal of Gerontology, 2022, v. 16, n. 3, p. 266, doi. 10.6890/IJGE.202207_16(3).0019
- By:
- Publication type:
- Article
Developing a Mathematical Model of Intracellular Calcium Dynamics for Evaluating Combined Anticancer Effects of Afatinib and RP4010 in Esophageal Cancer.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 3, p. 1763, doi. 10.3390/ijms23031763
- By:
- Publication type:
- Article
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10909-z
- By:
- Publication type:
- Article
Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-022-10428-3
- By:
- Publication type:
- Article
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-022-10467-w
- By:
- Publication type:
- Article
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
- Published in:
- Journal of Neuro-Oncology, 2021, v. 155, n. 3, p. 307, doi. 10.1007/s11060-021-03877-6
- By:
- Publication type:
- Article
Glucocorticoid reduces the efficacy of afatinib on the head and neck squamous cell carcinoma.
- Published in:
- Biocell, 2023, v. 47, n. 2, p. 329, doi. 10.32604/biocell.2023.023489
- By:
- Publication type:
- Article
Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer.
- Published in:
- PLoS ONE, 2024, v. 19, n. 6, p. 1, doi. 10.1371/journal.pone.0304914
- By:
- Publication type:
- Article